ClinicalTrials.gg

Program

depemokimab

Also written as “Depemokimab”, “GSK3511294 (Depemokimab)” and “Depemokimab (GSK3511294)”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps · Hypereosinophilic Syndrome · Churg-Strauss Syndrome, led by GlaxoSmithKline.

Furthest: phase 4, since Jul 9, 202618 company-led studies, 9 open or runningNext primary completion: Mar 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline189 open or runningphase 4since Jul 9, 2026Sep 15, 2017Mar 1, 2027phase 3 · NCT07671001

Also a collaborator on its studies: ppd-development-lp and iqvia-pty-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2017First study: phase 1 study in AsthmaFirst studyNCT03287310 · 50 enrolled · Germany, United Kingdom
  2. Jan 18, 20213 phase 3 studies in AsthmaNCT04719832, NCT04718389, NCT04718103
  3. Nov 22, 2021Phase 1 study in AsthmaNCT05140200 · 20 enrolled · China
  4. Feb 8, 20222 phase 3 studiesNCT05243680, NCT05263934
  5. Mar 2, 20222 phase 3 studies in Nasal PolypsNCT05274750, NCT05281523
  6. Apr 12, 2022Phase 3 study in Hypereosinophilic SyndromeNCT05334368 · 110 enrolled · United States, Argentina, Australia and more
  7. Oct 27, 2022Phase 1 study in AsthmaNCT05602025 · 140 enrolled · United States
  8. Apr 28, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT06959095, NCT06961214
  9. May 16, 2025Phase 3 study in AsthmaNCT06979323 · 150 planned · United States, Belgium, Canada and more
  10. Sep 15, 2025Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07177339 · 1,196 planned · United States, Australia, Bulgaria and more
  11. Mar 2, 2026Phase 3 study in AsthmaNCT07456033 · 456 planned · United States, United Kingdom
  12. Jun 22, 2026Phase 3 study in AsthmaNCT07671001 · 34 planned · United States
  13. Jul 9, 2026Phase 4 study in Nasal PolypsNCT07701967 · 28 planned · Japan

Ahead

  1. Mar 1, 2027Primary completion: phase 3 study in AsthmaNCT07671001
  2. Jun 28, 2027Primary completion: phase 4 study in Nasal PolypsNCT07701967
  3. Oct 29, 2027Primary completion: phase 3 study in Hypereosinophilic SyndromeNCT05334368
  4. Jan 5, 2028Primary completion: phase 3 study in AsthmaNCT06979323

TargetBeta

IL5 →read by rule
“Interleukin-5 inhibitor”ChEMBL 37, by rule

Other programs on IL5

ProgramCompanyFurthest phaseStudies
SHR-1703Jiangsu HengRui Medicinephase 37

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07701967Nasal Polyps · Japan4RecruitingJun 28, 202728
NCT07671001Asthma · United States3RecruitingMar 1, 202734
NCT07456033Asthma · United States, United Kingdom3RecruitingSep 23, 2030456
NCT07177339Pulmonary Disease, Chronic Obstructive · United States, Australia, Bulgaria and more3RecruitingApr 30, 20291,196
NCT06979323Asthma · United States, Belgium, Canada and more3RecruitingJan 5, 2028150
NCT06961214Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingDec 13, 2028961
NCT06959095Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more3RecruitingDec 13, 2028981
NCT05602025Asthma · United States1CompletedOct 23, 2023140
NCT05334368Hypereosinophilic Syndrome · United States, Argentina, Australia and more3Active, not recruitingOct 29, 2027110
NCT05281523Nasal Polyps · United States, China, Italy and more3CompletedJul 12, 2024264
NCT05274750Nasal Polyps · United States, Argentina, Belgium and more3CompletedJul 30, 2024276
NCT05263934Churg-Strauss Syndrome · United States, Argentina, Austria and more3Active, not recruitingSep 29, 2026163
NCT05243680Asthma · United States, Australia, Canada and more3CompletedMay 19, 2025641
NCT05140200Asthma · China1CompletedDec 23, 202220
NCT04719832Asthma · United States, Canada, China and more3CompletedNov 21, 2023395
NCT04718389Asthma · United States, Australia, Austria and more3CompletedSep 14, 20251,717
NCT04718103Asthma · United States, Australia, Canada and more3CompletedApr 11, 2024397
NCT03287310Asthma · Germany, United Kingdom1CompletedJul 31, 201950

How it is read

Names in the registry

  • “Depemokimab”, 11 entries
  • “GSK3511294 (Depemokimab)”, 3 entries
  • “Depemokimab (GSK3511294)”, 2 entries
  • “GSK3511294”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.